Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Februar...
February 17 2021 - 9:25AM
Conversion Labs, Inc. (NASDAQ: CVLB), a
leading direct-to-patient telehealth company, has been invited to
present at the BTIG Virtual MedTech, Digital Health, Life Science
& Diagnostic Tools Conference being held on February 17-19,
2021.
Conversion Labs CEO Justin Schreiber is scheduled to present in
a fireside chat on Thursday, February 18 at 1:00 p.m. Eastern time.
He will be joined by the company’s chief business officer, Corey
Deutsch, for the presentation and virtual one-on-one meetings with
institutional analysts and investors throughout the conference.
The presentation will be webcast live and available for replay
here and via the investor relations section of the company’s
website at ConversionLabs.com.
Management will discuss the company’s recently announced plans
to change its name to LifeMD on February 22. The name change will
be followed by the official launch of its subscription-based
primary care and concierge services designed to positively
transform all aspects of a patient’s healthcare. LifeMD’s
mobile-first interface will be powered by the company’s
proprietary Veritas MD digital health platform, providing
a seamless integration between doctors, patients, medical
information and pharmacy.
Management will also discuss the company’s
recently reported preliminary results for 2020, with
revenue up 205% to $38.0 million. The record month of December
ended the year at an annualized revenue run-rate of more than $60
million. Annual recurring revenue (ARR) generated by subscriptions
is expected to total $26.0 million at yearend 2020, up 525%
year-over-year.
Register for the conference here. To schedule a one-on-one
meeting with the company, please contact your BTIG representative.
To learn more about Conversion Labs, contact Ron
Both of CMA at (949) 432-7557 or submit your
request here.
About BTIGBTIG is a global financial services
firm specializing in institutional trading, investment banking,
research and related brokerage services. With an extensive global
footprint and more than 650 employees, BTIG, LLC and its affiliates
operate out of 18 cities throughout the U.S., and in Europe, Asia
and Australia. BTIG offers execution, expertise and insights for
equities, equity derivatives, ETFs and fixed income, currency and
commodities (futures, commodities, foreign exchange, interest
rates, credit, and convertible and preferred securities). The
firm’s core capabilities include global execution, portfolio,
electronic and outsource trading, transition management, investment
banking, prime brokerage, capital introduction, corporate access,
research and strategy, commission management and more. To learn
more about BTIG, visit www.btig.com.
About Conversion LabsConversion Labs, Inc.
is a leading telehealth company offering a full portfolio of
direct-to-patient products and services. The company combines
virtual medical treatment with prescription medications and unique
over-the-counter products. Its network of licensed physicians
offers telemedicine services and direct-to-consumer pharmacy to
consumers across the U.S. To learn
more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking
StatementsThis news release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, as
amended, regarding, among other things our plans, strategies and
prospects -- both business and financial. Although we believe that
our plans, intentions and expectations reflected in or suggested by
these forward-looking statements are reasonable, we cannot assure
you that we will achieve or realize these plans, intentions or
expectations. Forward-looking statements are inherently subject to
risks, uncertainties and assumptions. Many of the forward-looking
statements contained in this news release may be identified by the
use of forward-looking words such as "believe," "expect,"
"anticipate," "should," "planned," "will," "may," "intend,"
"estimated," and "potential," among others. Important factors that
could cause actual results to differ materially from the
forward-looking statements we make in this news release include
market conditions and those set forth in reports or documents that
we file from time to time with the United States Securities and
Exchange Commission. All forward-looking statements attributable to
Conversion Labs, Inc. or a person acting on its behalf are
expressly qualified in their entirety by this cautionary
language.
LifeMD™, Veritas MD™, Shapiro MD™, Rex MD™ and Nava MD™ are
trademarks of Conversion Labs. All other trademarks are the
property of their respective owners.
Company
Contact Conversion
Labs Email
Contact
Media and Investor Relations ContactRon Both or
Grant StudeCMA Investor RelationsTel (949) 432-7566Email
Contact
Conversion Labs (NASDAQ:CVLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Conversion Labs (NASDAQ:CVLB)
Historical Stock Chart
From Sep 2023 to Sep 2024